Overall findings indicate that increased EC risk for BRCA1/2 carriers has been associated with tamoxifen use for breast cancer prevention or treatment (since these genes confer high breast cancer risk) comparable to the risk observed in the general population [18,19]. The gene discussed is BRCA1; the disease is breast carcinoma.